[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357255-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357255-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","charleson-and-elixhauser-comorbidity-indices-in-predicting-mortality-among-young-and-old-cervical-cancer-patients","Charleson and Elixhauser Comorbidity Indices in Predicting Mortality Among Young and Old Cervical Cancer Patients","","Cervical cancer mortality varies substantially by region, and the study assesses how comorbidity burden relates to survival in young (\u003C50) and older (≥50) cervical cancer patients. A retrospective cohort used electronic medical records for women diagnosed between 2011 and 2021 in the southeastern US. Charlson Comorbidity Index and Elixhauser Comorbidity Index were estimated to evaluate 5-year and 2-year overall survival using Kaplan–Meier curves and multivariable Cox models, with discrimination compared via Harrell’s C-statistic.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/charleson-and-elixhauser-comorbidity-indices-in-predicting-mortality-among-young-and-old-cervical-cancer-patients/357255/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/charleson-and-elixhauser-comorbidity-indices-in-predicting-mortality-among-young-and-old-cervical-cancer-patients/357255.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What comorbidity indices were compared in predicting mortality?","Question",{"text":63,"@type":64},"The study compared the Charlson Comorbidity Index (CCI) and the Elixhauser Comorbidity Index (ECI) to predict survival outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was survival analyzed in young versus older cervical cancer patients?",{"text":68,"@type":64},"Survival was assessed using Kaplan–Meier methods and multivariable Cox proportional hazards models, stratified by age at diagnosis (\u003C50 vs. ≥50) and adjusted for baseline demographics.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the relationship between higher comorbidity burden and mortality?",{"text":72,"@type":64},"Higher comorbidity burden was associated with increased mortality in both age groups, with higher CCI scores and EC I scores (≥3) linked to worse 5-year survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357255,1790536001,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398046744996,"Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nCharleson and Elixhauser Comorbidity Indices in Predicting Mortality Among Young and Old Cervical Cancer Patients  \nAmruta Kulkarni1 | Howard W. Wiener2 | Teresa K. L. Boitano3 | Jeff M. Szychowski1 | Sadeep Shrestha2  \n1Department of Biostatistics, School of Public Health, UAB, Birmingham, Alabama, USA | 2Department of Epidemiology, School of Public Health, UAB,  \nBirmingham, Alabama, USA | 3Department of Obstetrics and Gynecology, Heersink School of Medicine, UAB, Birmingham, Alabama, USA Correspondence: Sadeep Shrestha ([sshrestha@uab.edu](sshrestha@uab.edu))  \nReceived: 1 July 2025 | Revised: 9 April 2026 | Accepted: 14 May 2026  \nKeywords: Charleson comorbidity index | Elixhauser comorbidity index | survival analysis | uterine cervical neoplasms  \nABSTRACT  \nIntroduction: Cervical cancer is the fourth leading cause of cancer deaths in women, and mortality varies significantly by region, with the highest rate in southeastern US. This study evaluated the association between comorbidity burden and cervical cancer survival and compared the prognostic performance of the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI) .  \nMethods: A retrospective cohort study was conducted using electronic medical records of women diagnosed with cervical cancer between 2011 and 2021 at a large academic hospital in southeastern US. CCI and ECI were estimated to assess 5-year overall survival using the Kaplan–Meier methods and multivariable Cox proportional hazard models, stratified by age at diagnosis (young \u003C 50 vs. old ≥50years) and adjusting for baseline demographics. Two-year survival analyses were also conducted. Predictive discrimination of CCI and ECI models was compared using Harrell's C-statistic.  \nResults: Higher comorbidity burden was associated with increased mortality across age groups. Compared with patients with no comorbidities (CCI = 0), CCI scores of 1–4 and ≥5 were associated with higher 5-year mortality among younger women (adjusted hazard ratio [aHR] = 2.35 (1.03–5.35); 2.80 (1.38–5.69), respectively) and older women (aHR = 2.38 (1.26–4.50); 1.43 (0.63–3.27), respectively) . ECI scores ≥3 were also strongly associated with increased 5-year mortality in both age groups. Both indices demonstrated acceptable and comparable predictive discrimination for 5-year survival in both age groups (C-statistics ranging from 0.74–0.70). Findings were consistent in 2-year survival analyses.  \nConclusion: Greater comorbidity burden is independently associated with worse survival among cervical cancer patients; highlighting the importance of comorbidity management in cervical cancer care.  \n1 | Introduction  \nDespite being one of the most preventable and treatable cancers, cervical cancer is the fourth most common cancer in women globally as well as in the United States [1] . According to the American Cancer Society's estimates, in 2026, more than thirteen thousand new cases of cervical cancer will be diagnosed in the US alone and more than four thousand women die from the  \ndisease annually [2]. Disparities exist with regards to geographic distribution, with patients from the Southeastern region of the US experiencing poorer outcomes when compared to individuals from other parts of the nation [3, 4] . Over the last few decades, the incidence and mortality rates of cervical cancer have declined due to effective population-based screening programs and HPV vaccines [5] . However, a recent study indicated that age-standardized incidence rates of cervical cancer increased  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71973 1 of 11  \n[","cbCaimJeQefMtqrU","https://ap.wps.com/l/cbCaimJeQefMtqrU","pdf",1294396,11,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What comorbidity indices were compared in predicting mortality?\",\"answer\":\"The study compared the Charlson Comorbidity Index (CCI) and the Elixhauser Comorbidity Index (ECI) to predict survival outcomes.\"},{\"question\":\"How was survival analyzed in young versus older cervical cancer patients?\",\"answer\":\"Survival was assessed using Kaplan–Meier methods and multivariable Cox proportional hazards models, stratified by age at diagnosis (\\u003c50 vs. ≥50) and adjusted for baseline demographics.\"},{\"question\":\"What was the relationship between higher comorbidity burden and mortality?\",\"answer\":\"Higher comorbidity burden was associated with increased mortality in both age groups, with higher CCI scores and EC I scores (≥3) linked to worse 5-year survival.\"}]","Charleson and Elixhauser Comorbidity Indices in Predicting Mortality Among Young and Old Cervical Cancer Patients | PDF",1790129493,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/525bb7444af09172f26f4dae2804e596.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a3751d12abbb70266ccdcd5f55c7438.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d23ccab57b69be1b00edd3c78842fc11.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82accce8c6a954afb69c04bb4b363d40.webp",980,1287]